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ABSTRACT
DNA topoisomerase II is a multidomain homodimeric
enzyme that changes DNA topology by coupling ATP
hydrolysistothetransportofoneDNAhelixthrougha
transientdouble-strandedbreakinanother.Toinvest-
igate the biochemical properties of the individual
domains of Leishmania donovani topoisomerase II,
four truncation mutants were generated. Deletion of
178 aminoacids from the C-terminus (core and Ld-
DC1058) had no apparent effect on the DNA-binding
or cleavage activities of the enzymes. However, when
429 aminoacids from the N-terminus and 451 amino-
acids from the C-terminus were removed (LdDNDC),
the enzyme was no longer active. Moreover, the
removal of 429 aminoacids from the N-terminus
(LdDNDC, core and LdDN429) render the mutant pro-
teinsincapableofperformingATPhydrolysis.Themut-
ant proteins show cleavage activities at wide range
of KCl concentrations (25–350 mM). In addition, the
mutant proteins, excepting LdDNDC, can also act on
kDNA and linearize the minicircles. Surprisingly, the
mutant proteins fail to show the formation of the
enhanced cleavable complex in the presence of
etoposide.Ourfindingssuggestthattheconformation
required for interaction with the drug is absent in the
mutant proteins. Here, we have also identified Tyr
775
through direct sequencing of the DNA linked peptide
as the catalytic residue implicated in DNA-breakage
andrejoining.Takentogether,ourresultsdemonstrate
that topoisomerase II are functionally and mechanist-
icallyconservedenzymesandthevariationsinactivity
seem to reflect functional optimization for its physio-
logical role during parasite genome replication.
INTRODUCTION
The participation of the DNA topoisomerases in a number of
vital processes, including replication, transcription, genetic
recombination, chromosomal decondensation and segrega-
tion is well documented (1). These enzymes catalyze the
transient breakage of DNA strands to form enzyme-
mediated gates through which an intact DNA strand or
a pair of DNA strands of a double helix can pass. DNA
topoisomerases can be divided into three sub-families,
namely type IA, type IB and type II on the basis of sequence
homology and mechanism of action (2). Type II DNA topo-
isomerases catalyze ATP-dependent passage of a DNA
segment through a transient double-strand break in another
segment. In such a reaction, the enzyme-mediated reversible
cleavage is generated by the trans-esteriﬁcation reactions
between a pair of active site tyrosines and two DNA
phosphodiester bonds staggered 4 bp apart. Eukaryotic topo-
isomerase II are dimeric, whereas its prokaryotic counterparts
including gyrase and topo IV are A2B2 tetramers. Moreover,
the N-terminal and the central parts of eukaryotic topo-
isomerase II are homologous to bacterial GyrB and GyrA
subunits, respectively.
Even though cells cannot survive without the double-
stranded DNA passage activity of topoisomerase II, the forma-
tion of a cleavage complex is potentially toxic. DNA
polymerases or helicases can convert such transient topoII-
DNA intermediates into permanent double-stranded DNA
breaks that can eventually trigger cell death pathways (3).
Besides its physiological activities, topoisomerase II is a target
for a number of antineoplastic and antiparasitic drugs (4,5).
Topoisomerase II inhibitors can be divided into topo II
catalytic inhibitors and topo II poisons (6). Topoisomerase
catalytic inhibitors like bis-dioxopiperizines do not stabilize
DNA cleavage complexes whereas topo II poisons inhibit the
enzyme by increasing the steady-state levels of DNA cleavage
complexes (7,8).
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doi:10.1093/nar/gki527Despitethe importanceofDNAcleavage/religationreaction
to the function of topoisomerase, relatively little is known
about the speciﬁc enzyme–DNA interaction that drives
this reaction. Therefore, the molecular interaction of
LdTOP2 and DNA remains an enigma. In conjunction
with this fact, even though topoisomerase II from protozoan
parasites have been cloned and sequenced (9), the mechanistic
features of the enzyme have never been explored. In kineto-
plastid parasites topoisomerase II undoubtedly function
at several steps in the minicircle replication processes,
decatenation of the parental circles from the network and
recatenation of the daughter circles to the network (10).
In Leishmania donovani, we had previously reported the
existence of a type II topoisomerase containing 1236 amino-
acids localized both in nucleus and kinetoplast (11). Given
the importance of cleavage/religation reactions mediated by
topoisomerase in the life cycle of the parasite, in the present
study we report the properties of the DNA-binding domain
of LdTOP2.
In human topoisomerase IIa a fragment from aminoacid
1–439 was shown to have an intrinsic ATPase activity (12),
which could be stimulated by DNA. In another study, the core
domain of drosophila topoisomerase II covering aminoacid
406–1207 was demonstrated to have wild-type levels of cleav-
age and religation activities (13). These results indicate that
the individual domains in topoisomerase II preserve their
intrinsic activities even when separated from the rest of the
enzyme, demonstrating that they fold up as independent
catalytic domains.
In the present study, to further investigate the biochemical
properties of the DNA-binding or core domain of LdTOP2,
wehave constructedfourtruncationmutantsnamelyLdDN429
(aminoacid residues from 430–1236), core (aminoacid resi-
dues 430–1058), LdDC1058 (aminoacid residues 1–1058) and
LdDNDC (aminoacid residues 430–785). The mutant proteins
have been characterized with respect to ATPase, DNA-
binding and cleavage activities. Our results indicate that the
residues from 1–1058 which mimics the wild-type enzyme
in complementing the temperature-sensitive topoisomerase
II mutant yeast strain (14), retains its DNA-dependent ATPase
activity and can also perform cleavage of supercoiled DNA.
Moreover, the catalytic amino acid implicated in DNA break-
age and reunion was mapped by sequencing the DNA bound
protein. Taken together, this is the ﬁrst report that demon-
strates the domain demarcations of LdTOP2 and provides
an insight into the mechanistic aspects of the core/DNA-
binding domain of the protein and the catalytic residue
implicated in DNA breakage and rejoining.
MATERIALS AND METHODS
Construction of truncation mutants
For construction of all truncation mutants, the regions cor-
responding to amino acids 430–785, 430–1058, 430–1236
and 1–1058 were ampliﬁed by PCR. For aminoacids 430–
785 (1 kb DNA fragment), aminoacids 430–1058 (1.9 kb
DNA fragment), aminoacids 430–1236 (2.4 kb DNA frag-
ment), the sense primer used was 50 GGGAATTCCATATGA-
CAGAGGGTGACTCGGCG 30 and the antisense primers
were 50 CGGGATCCCTTGTACAAGTCAAGGCG 30,
50CGGGATCCGATGTAGTCGAAGCTCTC30 and 50CGG-
GATCCCCCGCTTCACATGCTCCCCTTACA 30, respect-
ively. For the construction of 1–1058 (3.2 kb) mutant, the
sense and the antisense primers used were 50 GGGAATTC-
CATATGACAGACGCTTCCAAG- 30 and50 CGGGATCCT-
CTAGAGAAGCTCTCGTCCACGCG- 30 respectively. The
ampliﬁedproductswere cloned inthe NdeI andBamHI sites of
bacterial expression vector pET16b (Novagen) and expressed
in Escherichia coli BL21 (DE3) pLysS. The full length
LdTOP2 was cloned in the BamHI and HindIII sites of expres-
sion vector pET28C, using sense primer 50-CG GGATCCT-
CATGACAGACGCTTCCAAG-30 and anti sense primer 50-
CCCAAGCTTCATCAAAACATGTGGCAG-30. PCR was
performed for 30 cycles of denaturation at 94 C for 45 s,
annealing at 52.5 C and extension at 68 C for 1 kb/min
using Pwo polymerase (Roche Applied Science) and
200 mM of each dNTP.
Expression and protein purification
Expression from constructs pET16b/1, pET16b/1.9, pET16b/
2.4, pET16b/3.2 and pET28c/3.7 yielded 40, 70, 89, 116 and
137 kDa proteins, respectively. Puriﬁcation of all the His-
tagged proteins was done as follows. Brieﬂy, the cells con-
taining the recombinant plasmids were induced at 0.6 OD600
with 0.5 mM IPTG at 22 C for 10 h. The cells were harvested
and resuspended in phosphate buffer (pH 7.8) containing
300 mM NaCl, 200 mg/ml lysozyme, 0.1% Triton X-100,
0.25% Sarkosyl and 1 mM PMSF. Final lysis was achieved
by sonication on ice and the lysate was cleared by centrifu-
gation at 12 000 rpm in a SS34 rotor for 20 min. The cleared
lysate was passed through Ni- nitrilo triacetic acid (Ni-NTA)
agarose column (Qiagen). After washing with phosphate buf-
fer (pH 7.8) containing 300 mM NaCl and 30 mM imidazole,
elution was done using 250 mM imidazole. For further puri-
ﬁcation, the fractions were pooled from Ni
2+ column, dialyzed
and loaded onto a 2 ml packed phosphocellulose column (P11
cellulose, Whatman). The column was washed with 10 ml of
wash buffer (50 mM Tris–HCl, pH 7.5, 0.5 mM EDTA and
20% glycerol) containing 600 mM KCl and ﬁnally eluted with
the same buffer containing 800 mM KCl. After elution the
peak fractions were dialyzed overnight against storage buffer
containing 10 mM Tris–HCl (pH 7.8), 100mM NaCl, 5 mM
MgCl2, 1 mM PMSF and 15% glycerol and stored at  70 C
until further use.
ATPase assay
ATPase measurements were carried out by the pyruvate
kinase/lactate dehydrogenase assay described previously
(12) with the following modiﬁcations. Reaction mixture
(1 ml) contained: 0.1 mM NADH, 2 mM phosphoenol-
pyruvate, 3 units of pyruvate kinase and 4 units of lactate
dehydrogenase. Reactions were initiated by mixing the
reaction mixture and ATP, both pre-equilibrated to 30 C.
Decrease in NADH concentration was monitored by measur-
ing the absorbance at 340 nm in a UV-visible spectrophoto-
meter (Shimadzu Corp.) All assays were performed in
triplicate.
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The labeling of 36 mer oligonucleotide 1 (50ATGAAATCT-
AACAATGCGCTCATCGTCATCCTCGGC30) containing
high afﬁnity topoisomerase II binding site (15) was done
using polynucleotide kinase (Invitrogen). The labeled
oligonucleotide 1 was annealed to oligonucleotide 2 (50
TACTTTAGATTGTTACGCGAGTAGCAGTAGGACCG 30)
in a buffer containing 40 mM Tris–HCl (pH 7.5), 20 mM
MgCl2 and 50 mM NaCl at 70 C for 1 h and allowed to
cool down slowly to room temperature. Brieﬂy, the reaction
was done in a 20 ml binding buffer containing 50 mM Tris–
HCl (pH 7.5), 1 mM DTT, 4 mM MgCl2, 50 mM KCl and
15mg/ml BSA and 5pmol of 36 bp duplex oligonucleotide and
varying concentrations of wild type and truncated LdTOP2
enzymes. Reaction mixtures were incubated at 4 C for 30 min
and electrophoresed through 7% non-denaturing polyacry-
lamide gel (acrylamide:bis:: 29:1) in 0.25· TBE and auto-
radiographed. Quantitation of the unbound oligonucleotide
was done by densitometry and Kd was estimated from protein
concentration at which half of the duplex oligonucleotide was
bound to the protein (16).
Cleavage reaction
Cleavage reaction was performed as described (17). A 20 ml
reaction mixture contained 200 ng negatively supercoiled
pRYG DNA, 10 mM Tris–HCl (pH 7.5), 100 mM KCl,
0.1 mM EDTA, 5 mM MgCl2, 0.5 mM DTT, 30 mg BSA
and 10 pmol of enzymes. Reaction was started by incubating
at37 Cfor30minandterminatedbytheadditionof0.5%SDS
and 10 mM EDTA. The mixture was further incubated with
100 mg/ml proteinase K at 37 C for 30 min and analyzed by
electrophoresis on a 1% agarose gel. Ethidium bromide at a
ﬁnal concentration of 0.5 mg/ml was included in the gel to
resolve the linear product (Form III) from the supercoiled
molecule (Form I). Control assays always contained an
amount of drug diluent (Dimethyl sulfoxide) equivalent to
that present in drug containing reaction. Salt dependence of
the mutant enzymes was determined by performing cleavage
reaction as described above, using varying concentrations of
salt. When KCl dependence was estimated, Mg
2+ concentra-
tion was kept at 5 mM and for Ca
2+ and Mg
2+ requirement,
KCl concentration was kept at 100 mM.
DNA relaxation
DNA relaxation reactions containing 0.5 mg of negatively
supercoiled pRYG DNA were carried out in the absence or
presence of etoposide in 25 mM Tris–HCl(pH 7.9), 10 mM
MgCl2, 0.1 mM EDTA, 1 mM DTT, 2 mM ATP, 100 mM
NaCl, 10% glycerol and 500 ng of recombinant L.donovani
topoisomerase II. Following incubation at 37 C for 30 min,
the reaction was terminated by the addition of loading buffer.
The products were analyzed by gel electrophoresis in 1%
agarose gel, stained with ethidium bromide and photographed
under UV Transillumination.
Cleavage of kDNA
Plasmid pGEM4Z was used to clone the full-length
L.donovani minicircles sequence resulting in the formation
of pLURKE3 (18). The insert was excised with EcoRI and
radiolabeled by random priming using [a
32P]dCTP
(Amersham pharmacia) and used as a probe. As described
previously, (19) kinetoplast DNA (kDNA) was isolated from
Leishmania strain UR6. About 200 ng kDNA was incubated
with50 pmol enzyme for 30minat37 C inthe cleavage buffer
mentioned above. DNA was transferred from agarose gel to
nitro cellulose membrane. The membrane was hybridized with
radiolabeled E3 probe.
Covalent complex between truncated LdTOP2 enzymes
and radiolabeled DNA
Covalent complex between protein and DNA was formed as
described (20). Reactions were initiated with 50 pmol trun-
cated LdTOP2 enzymes (70, 89 and 116 kDa) in the cleavage
buffer mentioned above, containing 4ng
32P-labeled negat-
ively supercoiled pRYG plasmid DNA. Reactions were
quenched with NaOH and neutralized with HCl. DNase
(FPLC pure, Amersham pharmacia) treatment was done for
1ha t3 7  C. Reactions were terminated by the addition of
0.5% SDS and 10 mM EDTA before the complexes were pro-
cessed through two cycles of a Sephadex G-25 spin column
and proteins were precipitated and separated by SDS–
PAGE. The gel was dried and autoradiographed to expose
the protein bands.
For thin layer chromatography, the protein-DNA complexes
puriﬁed through G-25 column were treated with proteinase K
at 37 C for 30 min the digested products were vaccum dried
and re-suspended in 30 ml of constant boiling with 6N HCl.
After removal of HCl, the hydrolysates were dried under
vaccum and redissolved in H2O containing unlabeled phos-
phoserine, phosphotyrosine andphosphothreonine. The hydro-
lysateswerespottedonsilicagelplateandchromatographedin
a solvent containing ethanol/n-butyl alcohol/ammonia/water
(volume ratios 4:1/:2:3). After drying, the plates were sprayed
with 0.25% ninhydrin in acetone and heated to 65 Ct o
visualize the phospho aminoacid standards. The radioactive
signals of the phospho aminoacid were detected by autoradio-
graphy (21).
Preparation of LdTOP2-derived tryptic peptide
covalently linked to DNA
A1 0 0ml mixture containing the protein and
32P labeled pRYG
DNA was incubated in the above-mentioned cleavage buffer
at 37 C for 10 min. SDS was added to a ﬁnal concentration
of 0.5% to form a covalent complex between DNA and protein.
The protein DNA complex was subjected to SDS–PAGE elec-
trophoresisandstainedwithCoomassiebrilliantblue.Theprotein
band was excised and in gel trypsin digestion was performed.
The trypsin-digested peptides were fractionated by reverse
phase HPLC. Aliquots of the fractions were assayed for
32P.
The positive fraction was subjected to Edman sequencing.
RESULTS
Expression of N-terminal deletion mutants and
core domain of LdTOP2
In order to study the function of core domain of kinetoplastid
toposiomerase II, we constructed four truncation mutants of
L.donovani topoisomerase II (1236 amino acids). The trunca-
tion start points and end points were determined on the basis of
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dues have an intrinsic ATPase activity (T. Sengupta,
M. Mukherjee, A. Das, C. Mandal, R. Das, T. Mukherjee
and H. K. Majumder, unpublished data) and 1–1058 amino
acids can decatenate kDNA and complement temperature-
sensitive mutant yeast strain (14). So, to further investigate
the interaction of DNA with the core domain (homologous to
the core/ DNA-binding domain of other eukaryotic topoi-
somerase II), we constructed four truncation mutants of
LdTOP2 containing amino acids 430–785 (LdDNDC), 430–
1058(core), 430–1236 (LdDN429) and 1–1058 (LdDC1058)
(Figure 1A). All the mutants were generated by PCR ampli-
ﬁcation of the full-length LdTOP2 gene using site-speciﬁc
primers. The PCR products were cloned in pET16b and trans-
formed in E.coli BL21 (DE3) plysS. The bacterial cells har-
boring the truncation constructs were induced with 0.5 mM
IPTG and the resultant overexpressed proteins were puriﬁed
by Ni-NTA agarose, as the mutant enzymes had six histidine
residues at their N-terminus, and the wild-type LdTOP2 had
histidine tagged both at the N-terminus and the C-terminus.
Further puriﬁcation was achieved by passing the Ni-NTA
eluate through the phosphocellulose column as described in
Materials and methods (Figure 1B).
ATPase activity
It is known that upon binding to ATP, topoisomerase II under-
goes a conformational change that triggers double-stranded
DNA passage (20). We checked if any of the mutant proteins
retain their ATPase activities. Apart from the wild-type
enzyme, only the 116 kDa enzyme (1–1058 aminoacids
residues) had an ATPase activity. Moreover, the ATPase
activity of this protein was found to be stimulated by DNA
(Figure 2A). The KM of the 116 kDa protein was found to be
0.33 mM and 0.55 mM in the presence and absence of DNA,
respectively (Figure 2B). DNA was found to stimulate its
activity 2-fold. These values are comparable with those of
the wild-type enzyme having KM of 0.32 mM and 0.50 mM
in the presence and absence of DNA, respectively (Figure 2C).
The truncation mutants bind to DNA in
gel retardation assay
Apolyacrylamidegelretardationassaywascarriedouttostudy
the DNA binding characteristics of LdTOP2 truncation
mutants. The linear DNA substrate was a 36 bp duplex con-
taining high afﬁnity topoisomerase II cleavage site (15). The
ability of LdTOP2 truncation mutants to bind the 36 bp duplex
was tested under standard gel retardation assay condition, as
describedinMaterials andMethods. Theconstructscontaining
amino acid 1–1058 (116 kDa), 430–1058 (70 kDa) and 430–
1236 (89 kDa) were able to bind to the oligonucleotide but
the construct containing amino acids 430–785 (40 kDa)
failed to bind to the duplex DNA. The electrophoretic
patterns were typical of the binding studies (Figure 2D). The
bound DNA migrated as a high molecular weight species as
compared to the unbound DNA. Since the electrophoretic
mobility of the complexed DNA was greatly retarded as com-
paredtothat ofthe freesubstrate,the amountofunbound DNA
could be quantitated directly by densitometric scanning. This
quantitation,inturn,allowedthestraightforwardcalculationof
bound plasmid molecules by subtraction from the total DNA
employed (Figure 2E). The Kd value of LdDC1058, LdDN429
and core were found to be 3.3, 4.09 and 4.2 nM, respectively,
while that of the wild-type enzyme was 3.0 nM.
Analysis of the cleavage activity of the mutant proteins
An essential step in the relaxation of supercoiled DNA is
the cleavage of DNA in both strands by topoisomerase II.
To test the possibility that a mutant enzyme can neverthe-
less cleave DNA via trans-esteriﬁcation and may possess a
normal level of cleavage activity, the puriﬁed mutant enzymes
were assayed for their cleavage of plasmid DNA. The 40 kDa
protein (430–785 amino acids residues) which does not bind to
DNA also fails to show any cleavage of supercoiled DNA
(Figure 3A), whereas all other puriﬁed proteins (70, 89 and
116 kDa and and the wild-type LdTOP2) cleave supercoiled
DNA. However, etoposide enhanced the formation of cleav-
able complex only by the wild-type LdTOP2 protein and did
not have any effect on the activities of the mutant proteins
A
B
Figure 1. Schematic representation of topoisomerase II of L.donovani and
purification of the truncated proteins. (A) A coordinate of Leishmania TOP2
peptide. (A) LdDC1058, (B)L d DN429, (C) Core, (D)L d DNDC protein. (B)
10% SDS-polyacrylamide gel showing purification of the truncation proteins.
Lanes 1–4, 2 mg of 40, 70, 89 and 116 kDa, respectively, purified through Ni-
NTA and phosphocellulose columns. The gel was stained by silver stain. Sizes
of molecular mass markers (MBI Fermentas) in kDa are shown.
Nucleic Acids Research, 2005, Vol. 33, No. 8 2367(Figure 3A). Furthermore, to show that the mutant enzymes
generated linear DNA (Form III) and not the nicked form
(Form II), pRYG DNA treated with restriction endonuclease
HindIII was used as a marker (Figure 3A). The wild-type
LdTOP2 was sensitive to etoposide (Figure 3B). LdTOP2
relaxed supercoiled pRYG DNA (Lane 1) and the formation
of topological isomers (lane 2) was inhibited by etoposide
(lanes 3–5).
AB
CD
E
Figure 2. Propertiesofthemutantproteins.(A)DependenceofATPaserateofthe116and137kDaproteinonATPconcentrationatconstantenzymeconcentration.
116 kDa (open square), 137 kDa (black triangle) in presence of DNA, 116 kDa (black square), 137 kDa (open triangle) in absence of DNA. The data shown are
mean–SDofthreeindependentexperiments.(B)TheKMwascalculatedfromtheLineweaver–Burkplot,116kDainabsence(opensquare),andinpresence(black
circle) of DNA respectively. (C) 137 kDa in absence (open circle) and in presence (black square) of DNA respectively. (D) DNA-binding activity of the truncated
LdTOP2 proteins. Lane 1, labeled 36mer duplex oligonucleotide; lanes 2–5, 36mer oligonucleotide incubated with 40, 70, 89 and 116 kDa. (E) Graphical
representation of the native gel shift assay. The percentage of unbound oligonucleotide present in gel was quantified by film densitometry and plotted against
protein concentration. The kd value was calculated from this graph, core (open circle), LdDC1058 (black triangle), LdDN429 (black square) and 137 kDa (open
diamond) respectively.
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decatenation (22). Virtually every step in the replication of
the massive kDNA network of kinetoplastid parasites entails
alteration in DNA topology. Such reactions are catalyzed by
DNA topoisomerases. Many compounds active against euka-
ryotic topoisomerase II have been reported to cause lineariza-
tion of the minicircles (10). To explore whether the mutant
enzymes having DNA-binding and cleavage activities could
interact with kinetoplast DNA of Leishmania, we investigated
if the mutant enzymes could linearize kDNA. As described
earlierkDNA isolated fromL.donovaniwas incubatedwiththe
mutant enzymes in the cleavage buffer. After a 30-min incuba-
tion at 37 C, the reaction was terminated by the addition of
SDS and EDTA and the cleavage products were subjected to
proteinase K digestion. The DNA was resolved by agarose gel
electrophoresis and transferred to a nitrocellulose membrane.
To examine the minicircle DNA, the blot was probed with
32P-
labeled E3. The predominant forms were found to be linear-
ized (Form III) minicircles (Figure 4A and B). To show that
the mutant enzymes generated linearized minicircles, kDNA
treated with restriction endonuclease PstI was used as control.
A comparison of the activities of all mutants have been
summarized in Table 1.
Salt dependence of cleavage reaction
To investigate the characteristics of the truncated proteins in
the cleavage of DNA, assays were performed under various
KCl concentrations keeping the wild-type enzyme as control.
The analysis revealed that the mutant enzymes were active
over a wide range of salt concentrations from 25–300 mM,
while the activity is inhibited at 400 mM KCl concentration
(Figure 5A).
Topoisomerase II requires divalent cations at two separate
catalytic centers, the DNA cleavage/religation center and
the ATP binding/hydrolysis center. In our previous study
(T. Sengupta, M. Mukherjee, A. Das, C. Mandal, R. Das,
T. Mukherjee and H. K. Majumder, unpublished data), we
have observed that Mg
2+ is required for enzyme-mediated
ATP hydrolysis by the N-terminal domain of LdTOP2. In
the present study, we show the effect of Mg
2+ and Ca
2+ on
the cleavage activity mediated by the core domain of the
enzyme. Our results show that Mg
2+ as well as Ca
2+ can
support cleavage activity mediated by LdTOP2 (Figure 5B
and C), the optimum conditions for cleavage being 4 mM
Ca
2+ and 6 mM Mg
2+, respectively.
Active site mapping of L.donovani topoisomerase II
Since all the proteins were observed to have similar binding
and cleavage patterns, the 70 kDa core protein was selected for
active site mapping and was incubated with
32P-labeled pRYG
DNA in cleavage buffer. After incubation at 37 C for 30 min,
the mixture was treated with KOH to capture the covalent
protein-DNA complex, then digested with protease-free
DNase I and separated by SDS–PAGE. This procedure yields
a single broad band migrating at 70 kDa (Figure 6A), thus
localizing the catalytic residue in the 70 kDa core domain.
In order to investigate the chemical nature of the covalent
linkage formed between the substrate DNA and LdTOP2,
biochemical mapping studies were carried out by labeling
the puriﬁed enzyme as described above. Acid hydrolysis of
A
B
Figure3.Comparisonofcleavageactivityofthetruncatedproteins.(A)Lane1:negativelysupercoiledpRYGDNA;lanes2,4,6,8and10,cleavageby40,70,89and
116kDaandthefulllengthLdTOP2proteinrespectively.Lanes3,5,7,9and11,sameaslanes2,4,6,8and10butinthepresenceof20mg/mletoposiderespectively.
Lane 12, pRYG DNA digested with Hind III restriction enzyme. (B) Lane 1: negatively supercoiled pRYG DNA only, Lane 2: same as lane 1 but with 500 ng
topoisomeraseII,Lane3,4and5sameasabovebutwith20,50and100mg/mletoposiderespectively.Positionsofsupercoiledmonomer(SM)andrelaxedandnicked
monomer are indicated (RL/NM).
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that was found to co-chromatograph with chemically synthes-
ized phosphotyrosine on thin layer silica gel in the solvent
system mentioned in Materials and Methods (Figure 6B).Thus
the covalent linkage formed between the L.donovani enzyme
and DNA was Tyr-P, as observed, for other eukaryotic topo-
isomerase II.
An unambiguous way of identifying the active site of topo-
isomerase II for the breakage and rejoining of its substrate is to
form the covalent enzyme-DNA complex, digest the complex
with an endopeptidase and sequence the DNA-linked peptide.
The peptide sequence directly reveals the position of the PO4-
linked amino acid in the topoisomerase polypeptide chain. The
sequencing of the active site residue of LdTOP2 was done as
described in Materials and Methods. To minimize the inter-
ference of DNA with the aminoacid sequencing, the protein
was kept in molar excess. The protein-DNA complex was
subjected to SDS–PAGE and stained with Coomassie brilliant
blue. The protein band was subsequently excised and subjec-
ted to ingel trypsin digestion. The resultant peptides were
analyzed for the presence of
32P and the positive fractions
were subjected to Edman degradation. The ﬁrst cycle resulted
in an aminoacid with altered retention time. The next four
cycles contained Isoleusine, Phenylalanine, Threonine, Lysine
and ‘blank’, respectively. When this sequence was compared
to LdTOP2 sequence, it was found that the pattern correspon-
ded exactly to that of Tyr
775-Ile
776-Phe
777-Thr
778-Lys
779, with
Tyr
775 being the point of covalent attachment to DNA (thus
came at an altered retention time). Furthermore, aminoacid
774 of LdTOP2 is Arginine; and trypsin would be expected to
cleave after this position as well as after Lys
779, to give ﬁve
aminoacids linked to DNA.
DISCUSSION
Being an essential enzyme, DNA topoisomerase II is con-
served among species and has retained the domain organiza-
tion and motifs important for catalysis and function. However,
there must be speciﬁc differences in the catalytic properties
and efﬁciency of the enzyme from different sources. The
enzyme activity has to be optimized for physiological function
and this aspect of the parasite protein has not been addressed
AB
Figure 4. Topoisomerase II induced linearization of minicircles. (A) Lane 1, kDNA isolated from Leishmania strain UR6. Lanes 2–4 same as lane 1 but incubated
with core, LdDN429, LdDC1058.Lane 5, kDNA isolatedfrom Leishmania strain UR6 digested with restriction endonuclease PstI. (B) The agarose gel in panel (A)
was transferred to nitrocellulose and probed with linearized E3 as described in Materials and Methods to detect the free minicircles.
Table 1. Comparison of the activities of wild type and mutant LdTop2 proteins
Mutants Aminoacids deleted ATPase Activity DNA-binding Cleavage activity
LdDNDC (40 kDa) 429 from N-terminus 451 from C-terminus (residues 430–785)     
Core (70 kDa) 429 from N-terminus 178 from C-terminus (residues 430–1058)   ++
LdDN429 (89 kDa) 429 from N-terminus (residues 430–1236)   ++
LdDC1058 (116 kDa) 178 from C-terminus (residues 1–1058) ++ +
LdTOP2 (wild type) 1236 amino acid ++ +
2370 Nucleic Acids Research, 2005, Vol. 33, No. 8so far. In the present study, we have carried out the charac-
terization offour truncationmutants of LdTOP2: LdDC1058, a
116kDa protein having 178 aminoacids deleted from the
C-terminus (14), an 89 kDa protein (LdDN429) lacking the
N-terminal 429 amino acid, a 70 kDa core domain, which has
the hydrophilic C-terminus as well as 429 aminoacids from the
N-terminus also removed and a 40 kDa protein, which lacks
the N-terminal as well as the C-terminal ends. In order to
determine whether the individual domains of LdTOP2 still
retain activities, we analyzed the capabilities of the deletion
mutants to hydrolyze ATP. Only the 116 kDa enzyme (1–1058
aminoacids residues) retained its DNA-stimulated ATPase
activity (Figure 2A), which was comparable to the full length
LdTOP2 protein. This can be attributed to the fact that only
this protein retains the N-terminal homolog of GyrB having an
intrinsic ATPase activity. Studies with fragments of DNA
gyrase or eukaryotic topoisomerase II or with full-length
enzymes have shown a stimulatory effect of DNA on topo-
isomerase II catalyzed ATP-hydrolysis (12,23,24). Wang and
co-workers have recently shown that the stimulatory effect of
DNA on the ATPase activity of topoisomerase II fragments
increases if the enzyme fragment besides the N-terminal
ATPase domain also contains the B’ region of the enzyme
(25). This correlates with our previous observation that ATP
hydrolysis by the N-terminal 1–385 fragment fails to be stimu-
lated by DNA (Sengupta et al., unpublished data), while the
present study shows that the stimulation by DNA increases
2-fold as the length of the enzyme increases. Further, the
DNA-stimulated ATPase activity of the E.coli holoenzyme
varies from 2- to 100-fold, while yeast and calf thymus topo-
isomerase II show 20- and 4-fold stimulation of ATP hydro-
lysis by DNA (26).
It has been shown earlier in the case of drosophila that
deletion of ATPase domain and C-terminal tail of topo-
isomerase II does not affect its DNA breakage and rejoining
activity(13). Consistent with this, our results also show that all
the truncation mutants except the 40 kDa protein retain DNA-
binding and cleavage activity. The 40 kDa protein fail to show
DNA-binding and cleavage activities, probably due to the
inability of the protein to form a dimer as the putative
dimer interface was earlier mapped between the amino acid
residues 1022–1037; and the deletion of this region results
Figure 6. Radiolabeling of the core domain. (A) 70 kDa (core) enzyme was
incubated with
32P-labeled pRYG DNA, denatured, digested with DNaseI,
separated by SDS–PAGE and visualized by autoradiography (lane 1). Lane
2 same as lane 1 but subjected to SDS–PAGE after protease treatment. (B)
Identification of phospho aminoacid linkage in the hydrolysate of core
LdTOP2-DNA covalent complexes. Lane 1 represents the migration of
32P-
labeled acid hydrolysates. Lane 2 shows migration profile of standard cold
phosphoaminoacids. The positions of the marker compounds (seen by ninhy-
drin staining) are indicated by dotted lines. The pointof application of samples
is marked as Ori.
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Figure 5. Salt dependence of cleavage activity of the mutant proteins.
(A) Graphical representation of the extent of covalent complex formation
plotted as a function of KCl concentration. (B) Graphical representation of
the extent of covalent complex formation plotted as a function of Mg
2+
concentration. (C) Graphical representation of the extent of covalent
complex formation plotted as a function of Ca
2+ concentration where
vertical shaded bar is LdDC1058, gray bar is LdND429, black bar is core
protein and horizontal shaded bar is 137 kDa protein in all cases.
Percentage of cleavage was calculated as described above.
Nucleic Acids Research, 2005, Vol. 33, No. 8 2371in a protein which cannot complement temperature-sensitive
mutant yeast strain (14). Cleavage assay by various truncation
mutants reveals an optimum cleavage at 200 mM KCl con-
centration but the enzymes are active even at 300 mM KCl
concentration. This is in contrast to the results obtained in case
of yeast and human topoisomerase II, where maximum cleav-
age activity is observed at 100–150 mM KCl concentration but
no cleavable complexes are apparent above 225 mM KCl
concentration (27). It is well established that the strength of
a given protein-DNA interaction is inversely related to salt
concentration (28). The Kd of LdDC1058 is 3.3 nM and that of
the core and LdDN429 is 4.2 nM and 4 nM, respectively, while
the Kd of the full length enzyme is 3.0 nM. This value is
about  7-fold higher than E.coli gyrase but  3-fold lower
than Mycobacterium segmentis (26). This value is much lower
than the dissociation constant of human topoisomerase II for
fourway junction DNA (29 nM) and linear DNA (130 nM)
as shown by gel retardation assay (29). L.donovani topo-
isomerase II truncation mutants can perform cleavage of
DNA at high salt. It may be attributed to the fact that this
enzyme has high afﬁnity for DNA and a large amount of salt is
required to break the interaction between the core domain
of LdTOP2 with DNA. This also correlates with the fact
that LdDC1058, which has highest activity at 200 mM salt
concentration, has the lowest Kd value among the mutants.
The type II A subfamily of DNA topoisomerases, to which
LdTOP2 belongs, shares an important catalytic property with
type IA DNA topoisomerase in their common requirement for
Mg
2+ in catalysis. In contrast, the type IB subfamily enzymes
(represented by human topoisomerase I, vaccinia virus topo-
isomerase I and even L.donovani topoisomerase I) do not
require divalent ions in their catalytic mechanism (30).
Although cleavage assay by topoisomerase II is supported by
a numberof divalent cations includingMg
2+ and Co
2+ (31), we
havealsousedCa
2+fortworeasons.First,allknowneukaryotic
topoisomerase II generate higher cleavage in the presence of
Ca
2+ ions than in the presence of Mg
2+ ions (32,33). Calcium-
promoted, drug independent DNA cleavage sites induced by
yeast and human wild-type topoisomerase II and E.coli gyrase
havebeenreported(33,34).Apartfromtheincreasedcleavage,
the major properties of DNA scission including salt require-
mentsandnucleotidespeciﬁcityareretainedinCa
2+containing
reactions. Second, Ca
2+ inhibits a low level of exonuclease
activity sometimes evident in Mg
2+ containing reactions. It
was observed that DNA cleavage activity was supported by a
broadrangeofMg
2+andCa
2+concentration(Figure5BandC).
However, the optimal level of cleavage was observed at 6 and
4 mM divalent cation concentration, respectively.
We have tested the sensitivity of the truncation constructs
towards the drug etoposide. In our study, we observed that
etoposidedoesnotenhancetheformationofthecleavablecom-
plex by the mutant proteins. Earlier studies have shown that
hypo phosphorylation of human topoisomerase II at the C-
terminus render cells resistant to etoposide and other cleavage
enhancingdrugs(35).Severalpointmutationsortruncationsat
the C-terminus of topoisomerase II that confer resistance to
drugs (36) have been identiﬁed. It has been shown for many
other multidomain proteins that truncation of the protein in
many cases renders it incapable of giving full activity or in
other cases makes it drug resistant (37,38). In the present
study, we report that the full length Ld TOP2 is inhibited by
etoposide. We have also observed that etoposide inhibits ATP
hydrolysis by the N-terminal 1–385 aminoacids of LdTOP2
(T. Sengupta, M. Mukherjee, A. Das, C. Mandal, R. Das,
T. Mukherjee and H. K. Majumder, unpublished data). But
here we have shown that etoposide fails to enhance the
formation of the cleavable complex by truncated LdTOP2,
whereas the cleavable complex formation is enhanced by the
wild-type enzyme. We propose that a full-length enzyme is
required for interaction with a drug. This study also provides
acluethatbesidescontainingregulatorysequenceslikenuclear
localizationsignalsanddimerizationdomain,theC-terminusis
involvedindruginteractionbutthispropositionrequiresfurther
experimental validation.
The direct sequencing of the DNA-linked core fragment
of LdTOP2 identiﬁed Tyr
775 as the active site residue of
the parasite protein. This tyrosine is conserved in all
known type II DNA topoisomerases. A clear expectation is
that the homologous tyrosine in each of the type II DNA
topoisomerases including tyrosine 785, 781, 783 and 804 of
Drosophila melanogaster, Schizosaccharomyces pombe, Sac-
charomyces cerevisiae, and human, respectively, (39–42) are
functionally identical to Tyr 775 of L.donovani topoisomerase
II. As noted previously in each of the above mentioned cases,
the active site tyrosine in LdTOP2 is also preceded by an
arginine residue likely to facilitate the participation of the
tyrosine residue in the trans-esteriﬁcation reaction.
The results presented in this study with the truncated
LdTOP2 proteins enhance our understanding in the following
ways: (i) they indicate a clear distinction between the regionof
LdTOP2 required for ATP hydrolysis and trans-esteriﬁcation
reaction, (ii) they demonstrate that the catalytic domain per se
is capable of recognizing the target sequence for trans-
esteriﬁcationreactionand(iii)ATPhydrolysis,whichiscrucial
for topoisomerase II function in vivo, is not required for DNA-
binding or cleavage. In summary, the present study demon-
strates that the core domain of LdTOP2 is involved in the
formation of a covalent complex with DNA, with Tyr 775
being the active site residue. This study also brings forth
the fact that the ATPase, DNA cleavage and the C-terminal
domain of LdTOP2 are relatively independent in topoi-
somerase structure, with all the domains working in conjunc-
tion for full topoisomerase activity. Our study also brings to
light the fact that in addition to containing NLS and dimer-
ization domain, the C-terminus of LdTOP2 contains elements
that are implicated in interaction with etoposide. Thus, a future
challenge will be the identiﬁcation of residues in the core, C-
terminal and ATPase domain of LdTOP2 that could aid in the
design of novel treatment strategies for drug-resistant parasites.
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